Updated:
Rigel Pharmaceuticals
Rigel Pharmaceuticals was founded in 1996 in South San Francisco, a fixture in the Bay Area biotech corridor.
Rigel Pharmaceuticals
Rigel Pharmaceuticals was founded in 1996 in South San Francisco, a fixture in the Bay Area biotech corridor. The company is led by Raul Rodriguez, who has served as President and CEO since 2006. Rigel's identity is anchored in immunology and hematology, tracing its research heritage to small-molecule drug discovery before evolving into a commercial-stage enterprise. The firm's strategy centers on developing and commercializing treatments for hematologic disorders and rare immune diseases. Its core asset is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to a previous treatment. The commercial footprint is concentrated in the United States. Beyond ITP, Rigel has expanded fostamatinib's investigation into warm autoimmune hemolytic anemia and other indications. The company's strategy includes a partnership model, exemplified by its licensing agreements for fostamatinib in specific territories and a collaboration with Kissei Pharmaceuticals in Japan. Rigel operates as a publicly traded company on the Nasdaq, a structure that makes its financial posture transparent but also subjects it to the capital-market pressures typical of small-cap biotechs. The company's revenue streams include product sales from Tavalisse, contract revenues from collaborations, and government contracts, including a notable partnership with the U.S. Department of Defense to study fostamatinib for acute radiation syndrome. In December 2023, Rigel announced a collaboration and license agreement with Kandi Therapeutics for an early-stage program, signaling continued pipeline activity. What structurally differentiates Rigel is its long-tenured CEO operating in a post-commercialization model without the deep pipelines of large pharma. Unlike a discovery-platform biotech that licenses early assets, Rigel owns and markets its primary asset directly, while leaning on government and corporate partnerships to fund pipeline expansion — a lean, hybrid model that keeps SG&A costs tightly coupled to a single, self-funded commercial engine.
General information
Firm type
Asset Manager
Year founded
1996
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Raul R. Rodriguez
President and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions and capital allocation at Rigel Pharmaceuticals?
As a publicly traded pharmaceutical company, Rigel does not operate as an investment firm. Capital allocation decisions — including R&D spending, business development, and licensing agreements — are made by the executive management team led by CEO Raul Rodriguez, under the oversight of a board of directors. The company's financial strategy is oriented toward funding clinical development and commercial operations, not managing a portfolio of external investments.
What is Rigel's primary commercial product and its market?
Rigel's primary commercial product is Tavalisse (fostamatinib disodium), an oral SYK inhibitor approved in the United States for the treatment of chronic immune thrombocytopenia in adults who have had an insufficient response to a previous treatment. The company markets Tavalisse directly in the U.S. through its own commercial infrastructure. It represents the firm's core revenue-generating asset and the foundation of its commercial transition from a research-stage entity.
Is Rigel Pharmaceuticals structured as a single family office or a venture firm?
Rigel Pharmaceuticals is neither a family office nor a venture firm. It is a publicly traded biotechnology company listed on the Nasdaq under the ticker RIGL. The firm discovers, develops, and commercializes therapies for hematologic disorders and immune diseases, funding its operations through product revenues, partnerships, contract research, and public equity markets.
Does Rigel participate in fund commitments or only direct internal development?
Rigel does not make fund commitments like an institutional allocator. The company funds internal research and development programs directly and enters into strategic collaborations and licensing agreements with other pharmaceutical firms, such as its partnership with Kissei Pharmaceuticals in Japan. These agreements often involve milestone payments and royalties rather than equity stakes in external funds.
What is the known posture of Rigel regarding co-investments or external partnerships?
Rigel actively engages in external partnerships to fund development and expand the geographic reach of its assets. The company has secured licensing agreements with partners like Grifols for certain territories and Kissei Pharmaceuticals for Japan and parts of Asia. It also pursues non-dilutive funding through government contracts, including a significant collaboration with the U.S. Department of Defense to evaluate fostamatinib for acute radiation syndrome.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: